177 results about "Tumor targeted" patented technology

The invention discloses a bovine serum albumin combined nano antibody and a preparation method and application thereof, the amino acid sequence of the bovine serum albumin combined nano antibody Nb1 is shown as SEQ.ID No.1, the nano antibody Nb not only has high affinity to bovine serum albumin, but also has good binding activity to both human serum albumin and mouse serum albumin, and the nano antibody Nb has high affinity to human serum albumin and mouse serum albumin. And the antibody has a relatively good broad-spectrum application range, and can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like.

The invention discloses a multi-angle particle therapy system without a rotating rack and a using method thereof, and relates to the technical field of particle therapy equipment, and the treatment system comprises an accelerator, an irradiation system, a control system, a patient supporting system and an imaging system. The patient supporting system comprises a containing and fixing device, a two-dimensional translation system, a rotating system and a multi-degree-of-freedom mechanical positioning system, the containing and fixing device is connected with the two-dimensional translation system, the two-dimensional translation system is connected with the rotating system, and the two-dimensional translation system controls the relative position of a patient and a rotating center; the rotating system rotates a patient to an appointed angle of a treatment plan or cooperates with the imaging system to obtain a three-dimensional image of the patient, and the irradiation system irradiates a tumor target area; the use method comprises the following steps: generating a treatment plan by reconstructing a three-dimensional CT image, and completing irradiation at different angles according to the treatment plan. According to the treatment system, multi-angle irradiation on a patient can be realized under the condition that a rotating rack is not used, and the manufacturing period and cost of the particle treatment system can be reduced.

The invention discloses a tumor radiotherapy dose calibration method, and relates to the technical field of tumor radiotherapy, and the method comprises the steps: collecting multi-modal data in real time through 4D-CT, MRI and the like, extracting dynamic features through space-time registration, calculating a risk organ dose ratio and a tumor target dose deviation rate, and constructing a comprehensive evaluation function. The method has the advantages that the multi-modal dynamic data of the tumor target area are synchronously collected in real time, the space-time joint registration algorithm and the time sequence weight factor are combined, the limitation that existing static calibration depends on fixed parameters is broken through, and the method is suitable for the multi-modal dynamic data of the tumor target area. According to the method, 95% dose coverage of a tumor target region is guaranteed, and meanwhile, organ-endangering peak value receiving amount is controlled within a certain range of a clinical tolerance threshold value, so that the risk of excessive irradiation of normal tissues is reduced, and the radiotherapy dose calibration precision is prompted based on the deviation rate of a traditional method.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention belongs to the field of tumor drug research, and particularly relates to a cell vesicle co-delivery system, an anti-tumor drug and application. The cell vesicle-like co-delivery system is constructed according to the following steps: co-transfecting a recombinant expression vector of tumor targeting protein or targeting peptide and a recombinant plasmid of circRNA of effector molecules related to pyroptosis to a tool cell, and collecting to obtain the cell vesicle-like co-delivery system, a recombinant expression vector of the tumor targeting protein or the targeting peptide contains a DNA sequence for coding MCP protein, and a recombinant plasmid of circRNA of an effector molecule related to pyroptosis contains a DNA sequence for coding MS2 protein. According to the cell vesicle co-delivery system provided by the invention, tumor cell death is directly induced by delivering the cell death related effector molecule RNA through the cell vesicles, the killing efficiency is high, the side effect is relatively small, and the problems of mass production and drug loading can be solved.

The present invention provides an antibody-drug conjugate, a preparation method thereof, and an application thereof. The structural formula of the antibody-drug conjugate is as follows. Among them, mAb is the anti-HER2 antibody trastuzumab; the conjugate is obtained by Michael addition of the thiol group obtained by reducing the inter-chain disulfide bond of mAb with the linker-irinotecan conjugate LD038; n ranges from 1 to 10. The binding activity and internalization activity of the antibody-drug conjugate to various tumor target cells are not affected; compared with the same type of antibody-drug conjugate, the antibody-drug conjugate PRO1102 synthesized by the preparation method of the antibody-drug conjugate of the present invention shows certain advantages in terms of in vitro cytotoxicity to tumor cells, anti-tumor activity in rats in vivo, and in vivo pharmacokinetics.

The invention relates to a tumor target volume segmentation method and device and a storage medium. The method comprises the following steps: acquiring a medical image containing a target tumor; segmenting the target tumor in a spatial dimension according to the medical image to obtain a plurality of first target volumes which are located in the target tumor and are not overlapped; grouping the plurality of first target volumes to obtain a plurality of target volume groups; wherein each target volume group comprises at least one first target volume, and the adjacent first target volumes in the plurality of first target volumes are located in different target volume groups. According to the tumor target volume segmentation method and device and the storage medium provided by the invention, continuous irradiation of adjacent areas can be avoided through differential irradiation of different target volume groups, so that accumulated damage to surrounding normal tissues is reduced.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide and a nuclide marker and application thereof. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The cyclic peptide can label a diagnostic nuclide for PET imaging, or a therapeutic nuclide for intra-tumor irradiation therapy, using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention relates to the technical field of image processing, in particular to a small intestine capsule endoscope target detection method which comprises the following steps: acquiring a small intestine capsule endoscope image; the method comprises the following steps: constructing an improved RT-DETR network, inserting an SCSA module between a backbone network and a neck network of the RT-DETR, and introducing a DFM module behind a three-branch Fusion module of the neck network; and the improved RT-DETR network adopts a Focaler-IoU loss function. According to the method, the problem that the accuracy of recognizing the tumor target by using the small intestine capsule endoscope image through RT-DETR needs to be further improved is solved.

The invention discloses a brain tumor detection method based on improved YOLO11, which aims at special properties of medical images and clinical requirements of brain tumor detection, and comprises the following steps: firstly, standardizing and dividing brain tumor medical image data; the method comprises the following steps: designing a multi-stage mixed expansion convolution residual module (BTSA-MFE), and embedding the BTSA-MFE modules in a backbone network and a neck network; designing a lightweight medical feature fusion module M IAFA, and embedding an MIAFA module in a backbone network; a medical image specialized dynamic adaptive internal intersection-to-union ratio loss module MDIOU is designed, bounding box regression is adaptively optimized through a tissue density sensing type dynamic proportion adjustment mechanism, and the positioning precision of tumor targets with fuzzy edges and irregular shapes is improved; after training is completed, the brain tumor medical image to be detected is input into the model, the detection result is output, and the detection precision is improved.

The invention belongs to the technical field of cellular immunity, and relates to a non-virus-dependent engineering induced pluripotent stem cell as well as a preparation method and application thereof. A coding gene of a chimeric antigen receptor is inserted into an SIRPA gene on a genome of the engineered induced pluripotent stem cell. According to the invention, iPSC cells are edited in a SIRPA gene position fixed-point insertion mode, simultaneous knockout of SIRPA and integration of an exogenous chimeric antigen receptor CAR are realized, and CAR-iMac can be further induced and differentiated, so that CAR-iMac is differentiated to mononuclear / macrophage tumor targeted cells, the phagocytic ability of CAR-iMac is enhanced, tumor antigens are further presented, the tumor immune microenvironment is improved, and the anti-tumor immunity is enhanced; the method effectively solves the corresponding problem of directly extracting the natural macrophages from the human body, reduces the production cost and the time cost, is beneficial to clinical application, and in addition, utilizes a non-virus-mediated gene editing means to remarkably improve the genetic silencing phenomenon.

The application provides a preparation method of a Chlorella-arsene composite drug delivery system and application thereof. The application prepares arsene nanosheets (ANs) through a liquid phase stripping method, and obtains catechol-polyethyleneimine nanoparticles (CA-PEI) through oxidation self-polymerization. The ANs and the CA-PEI are charge-absorbed to form CA-PEI loaded with ANs (CA-PEI@ANs), and then charge-absorbed with protein nucleus Chlorella (CP), so that a Chlorella-arsene composite drug delivery system (CP@CA-PEI@ANs) is successfully constructed. The preparation operation of the drug delivery system is simple, and the reproducibility is good, and the drug delivery system has a good application prospect. The protein nucleus Chlorella is used as a drug delivery carrier, so that the problems of high cost and complex synthesis process commonly existing in a targeted delivery carrier are solved, and the application has good tumor targeting effect, and is beneficial to better drug efficacy.

The present application relates to the field of immunology, and particularly relates to a novel IL-15 fusion protein and application thereof. The present application provides an IL-15 transmembrane fusion protein, which is applied to NK cells or CAR-NK cells, can significantly enhance the tumor killing function of NK cells and CAR-NK cells, and can effectively promote the proliferation of NK cells and CAR-NK cells. It provides an important basis for developing NK cell products armored by the IL-15 transmembrane fusion protein, which are independent of any tumor target, thereby reducing the cycle and cost of CAR-NK development. Meanwhile, the present application respectively carries out function research in blood tumors expressing CD19 and solid tumors expressing CD276, and the results indicate the broad-spectrum application prospect of the structure in tumors.

This invention discloses a KK-LC-1 targeting binding protein and its derivatives, a kit, and applications. The protein sequence of the KK-LC-1 targeting binding protein is shown in one of SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5. The KK-LC-1 targeting binding protein of this invention has a molecular weight of only about 17 kDa, approximately one-tenth that of an antibody, exhibiting good tissue penetration. Furthermore, its production process is simple and yields high quantities. The targeting binding protein of this invention demonstrates good targeting activity against KK-LC-1-positive tumors both in vivo and in vitro, and can be used for targeted tumor drug delivery, representing a potential drug for tumor immunotherapy. Simultaneously, a KK-LC-1 serum detection kit was developed using the targeting binding protein, enabling quantitative detection of KK-LC-1 levels in the human body.

Provided is a bispecific antibody targeting CD3 and a tumor target and a use of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region, and an Fc portion; the Fc portion comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein or fragment thereof of a first molecule, the binding protein or fragment thereof of the first molecule is linked to the N-terminal of the scFv fragment, and the C-terminal of the scFv fragment is linked to the N-terminal of the first Fc peptide fragment; the second antigen binding region comprises a binding protein or fragment thereof of a second molecule; and the first molecule and the second molecule are the identical, and the scFv fragment has CD3 binding activity.

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

This application provides a method for screening inhibitors targeting CYP7A1 and their use in the preparation of anti-liver cancer drugs, relating to the field of tumor targeted drug design technology. The method for screening inhibitors targeting CYP7A1 protein includes: using the crystal structure of human cholesterol 7α-hydroxylase as a receptor model, precise docking screening is performed using software to screen drug-like molecules with molecular weights of 250-500 Da and lipid-water partition coefficients of -1 to 5 from a compound database; a graph neural network active learning model is used to predict and rank the protein-small molecule binding affinity of compounds in the database; the ΔG between candidate molecules and CYP7A1 is calculated using molecular mechanics / generalized Born surface area methods, with molecules having ΔG ≤ -40 kcal / mol considered potential inhibitors. The inhibitors of this application do not rely on the enzymatic activity of CYP7A1 to achieve anti-tumor effects and do not significantly affect cholesterol and bile acid metabolism levels.

The invention discloses a real-time positioning method for a tumor target region and a gold label implant, and belongs to the technical field of tumor localization, and the method specifically comprises the following steps: implanting a gold label in a tumor region, constructing a gold label-tumor dynamic model through CT, and obtaining a respiratory phase feature vector; realizing space matching of the two-dimensional projection and the three-dimensional model by using an improved hybrid registration algorithm, and obtaining a tumor compound displacement vector; establishing a respiration-displacement correlation model through time sequence alignment, generating a tumor movement map containing a real-time position and a predicted trajectory, and updating the reference coordinate system; establishing a rigid safety boundary based on a gold label, analyzing soft tissue texture and a prediction trajectory in combination with a convolutional neural network to generate an elastic treatment boundary, and dynamically adjusting a dose weight of a non-label area; and finally, submillimeter-level dynamic tracking is executed through a multi-leaf collimator. The problems of tumor motion uncertainty and individual deformation difference are solved, and the target area coverage precision and the dose distribution reasonability are improved.

The invention relates to the technical field of medical instrument application, in particular to a universal labyrinth source applicator and a method for realizing multi-angle accurate implantation thereof, and aims to solve the problems of insufficient focus dose coverage, high treatment cost and high efficiency caused by the fact that a bare-handed implantation or printing mold guide implantation mode is generally adopted during cervical cancer radiotherapy. And the cervical cancer radiotherapy effect is finally influenced. According to the method, function design is carried out on the implantation path of the implantation needle of the source applicator, then the source applicator is placed in a mathematical coordinate system, image data are scanned through CT equipment, the vertical distance, namely the transverse implantation range, from the tumor target position to the uterine cavity tube is calculated, and then the depth, needing to enter the tumor, of the implantation needle is calculated according to the number of image layers from the tumor target position to the lower surface of the source applicator. After the needed needle insertion channels are predicted, the multiple needle insertion channels of the labyrinth insertion source applicator are selected for insertion, so that the radioactive source can accurately cover a tumor focus treatment area during tumor after-loading treatment, and the overall treatment effect of cervical cancer is greatly improved.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The application belongs to the technical field of medicine preparation, and particularly relates to a magnetic layered double hydroxide, a targeted drug-loaded nano preparation, a preparation method and application of a tumor-targeted drug-loaded nano preparation. The preparation method of the magnetic layered double hydroxide provided by the application can prepare Fe3O4 nanoparticles with small particle size, and further prepare the magnetic layered double hydroxide which can be used as a water-soluble drug carrier. The magnetic layered double hydroxide is used for preparing the targeted drug-loaded nano preparation and the tumor-targeted drug-loaded nano preparation, and can be used for delivering water-soluble drugs such as 5-fluorouracil. The tumor-targeted drug-loaded nano preparation has good dispersity and can be actively targeted to HepG2 cells with high FR expression, has a good inhibitory effect on liver cancer cells, and is expected to provide a potential new treatment system for magnetic chemotherapy.

The present invention discloses a bovine serum albumin-binding nanoantibody and its preparation method and application. The amino acid sequence of the bovine serum albumin-binding nanoantibody Nb1 is shown in SEQ.ID No.1. The nanoantibody Nb not only has a high affinity for bovine serum albumin, but also has good binding activity to human serum albumin and mouse serum albumin. It has a good broad-spectrum application range and can be widely used in enhancing drug half-life, tumor targeted therapy and imaging, immune detection or diagnosis, recombinant albumin purification or enrichment, etc.

The invention discloses an albumin coupling medicine as well as a preparation method and application thereof. The cathepsin B response type camptothecin albumin coupling drug is innovatively designed and synthesized by taking albumin as a carrier, the albumin coupling drug has good cathepsin B response drug release capability, efficient tumor targeted delivery of the drug is realized, camptothecin is responded and released in tumor cell lysosome, and the drug delivery efficiency is improved. The specific anti-tumor effect is achieved. The invention provides a regulation and control method in the aspects of preparation, drug loading capacity and in-vitro release of the albumin coupled drug, size effects in the aspects of cellular uptake, cytotoxicity, tumor targeting and retention are illustrated, and guidance is provided for designing an efficient and safe tumor drug delivery system.

This invention discloses a method for esophageal cancer tumor target region segmentation based on cross-modal feature fusion of PET / CT images. The method uses a Transformer-fused Attention Progressive Semantic Nested Network (TransAttPSNN) as the 3D segmentation model for esophageal cancer tumor target regions. The TransAttPSNN network has an AttPSNN backbone structure and includes two segmentation networks: one for PET streams and the other for CT streams. Transformer cross-modal adaptive feature fusion modules are embedded in the different feature levels of the two segmentation networks. Compared with existing technologies, this invention effectively improves the segmentation accuracy of esophageal cancer tumor target regions and achieves better segmentation performance.

The present invention relates to the technical field of tumor tissue positioning, and specifically to a method and system for automatic delineation of tumor radiotherapy target areas based on artificial intelligence. Based on RGB images and grayscale images of tumor tissue, the present invention first performs edge detection to extract grayscale connected domains. The grayscale similarity and distribution characteristics between pixels in each connected domain are analyzed, the tumor characterization degree is calculated, the high metabolic area is screened out and its position in the RGB image is located. For the first preset area, based on the difference and distribution characteristics of the pixel B channel value and the central area, a low infiltration characteristic factor is generated and the low infiltration area is delineated. Further, in the second preset area outside the low infiltration area, the diffusion characteristic factor is calculated by combining the R / B / G channel difference of the pixel, and the gradient value is fused to obtain the diffusion area, thereby automatically delineating the tumor tissue. The present invention can accurately segment the high metabolic area, low infiltration area and diffusion area in the tumor tissue, thereby improving the accuracy of automatic delineation of the tumor target area.

The invention discloses a process for synergistically inhibiting melanoma by carrying low-dose paclitaxel on nanoparticles based on immunoregulation. According to the invention, hyaluronic acid functionalized albumin nanoparticles are combined with low-dose paclitaxel, the tumor targeting property of the drug is improved by utilizing a nanotechnology, and meanwhile, the tumor immune microenvironment is regulated and the anti-tumor immune effect is enhanced by activating an STING pathway. Through the combination, the treatment effect of the medicine is improved, the side effect of the medicine is remarkably reduced, and a new strategy is provided for tumor treatment. High-efficiency delivery of low-dose paclitaxel is realized through the nano-carrier, the drug dosage is reduced, the toxicity is reduced, meanwhile, the antitumor activity of the paclitaxel is retained, a new thought is provided for clinical application of traditional chemotherapeutic drugs, the tolerance and life quality of patients are expected to be improved, polarization of M1 type macrophages is promoted by activating an STING pathway, and the antitumor activity of the paclitaxel is improved. Interferon and other inflammatory factors are released, CD8 + T cells are recruited and activated, and therefore the anti-tumor effect is achieved.

The invention discloses preparation and application of engineered cell membrane vesicles targeting tumor cells. According to the application, a drug-loading delivery system with a tumor targeting function is constructed through genetic engineering, CD6 molecules are highly expressed on the surface of membrane vesicles, and Il24 mRNA is encapsulated, so that an effective anti-tumor effect is achieved. The material design system is innovative, has very important significance for developing a novel tumor targeted drug delivery carrier, and provides important enlightenment for structural precision and functional diversification of the tumor targeted drug delivery carrier; meanwhile, the natural protection effect of cell membrane vesicles and a possible lysosome escape mechanism are combined, mRNA degradation is effectively avoided, and the intracellular delivery efficiency of mRNA is improved; through gene therapy and immunotherapy, the limitation of a single therapy is broken through, and a new design thought and theoretical basis are provided for tumor targeted therapy.

The invention provides a nano-drug system based on active drug self-assembly, a preparation method and application, CPT-C, MTX-C, ART and a lipid material are dispersed in an organic solvent, and a CMA (at) RGD-NPs nano-drug system is prepared through a film dispersion method. By constructing a nano drug delivery system with tumor targeting, ROS response release and multi-mode synergistic treatment, endogenous ferroptosis can be induced, and toxicity introduced by exogenous iron is avoided; a cGAS-STING pathway is activated, and natural and adaptive immunity is enhanced; and in combination with immunotherapy, a forward feedback loop is formed, and growth and transfer of TNBC are synergistically inhibited.

The invention discloses a chimeric antigen receptor T cell (CAR-T) of modular artificial antigen-natural antigen logic gating (MANAGE) and application of the chimeric antigen receptor T cell in treatment of solid tumors. At present, solid tumors still lack efficient targets capable of covering tumor cells of the same focus and crossing tumor species, and most solid tumor targets are also expressed on normal tissue cells. Therefore, the application of single-target CAR-T therapy in solid tumors is limited by tumor heterogeneity and non-tumor targeted toxicity (OTOT). According to the invention, proteins and antibodies of targeted tumor cells modified by the artificial antigen FITC are constructed, and CAR-T double-gated by the FITC and the natural tumor antigen is researched and developed. When the two compounds are combined for use, the toxicity of OTOT can be reduced, the range of applicable cells and tumor species can be expanded, the injection time of FITC can be regulated and controlled, the effect of CAR-T can be'switched ', cytokine syndromes can be reduced, and a new method is provided for solid tumor treatment.